Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 4,108 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Experimental 2 Clear all
Active, not recruiting Phase 2 Interventional

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06402331
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
FPI-2265
Drug
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Phase 3 Interventional

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

NCT05511922
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900 600 mg, Drug: KVD900 300 mg
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 31, 2026, 3:38 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

NCT05438329
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
DB-1305/BNT325, Pembrolizumab, BNT327
Drug · Combination Product
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
42
States / cities
Bullhead City, Arizona • Cerritos, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions

NCT00865657
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 31, 2026, 3:38 PM EDT
Not yet recruiting Phase 3 Interventional

MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation

NCT07632157
View directory record Official record
Conditions
Atrial Flutter With Rapid Ventricular Response
Interventions
Magnesium Sulfate 2g, Magnesium Sulfate 4g, Saline (0.9% NaCl)
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Phase 1 Interventional

A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer

NCT00736372
View directory record Official record
Conditions
Metastatic Cancer, Advanced Cancer
Interventions
PX-12
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Greenville, South Carolina • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants

NCT05515601
View directory record Official record
Conditions
Healthy
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
396 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Cypress, California • Daytona Beach, Florida • Dilworth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 31, 2026, 3:38 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Determination of the Safety and Efficacy of a Novel Oral Rinse on Oral Health

NCT04197427
View directory record Official record
Conditions
Plaque, Gingivitis
Interventions
Experimental Oral Rinse, Placebo
Device
Lead sponsor
You First Services
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CPI Training for Parents of Children With ASD

NCT03537261
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Parent-based Crisis Prevention Institute (CPI) physical management training program (P-CPI)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 12 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Phase 3 Interventional Results available

ORTHOVISC Shoulder Osteoarthritis Study

NCT00436969
View directory record Official record
Conditions
Glenohumeral Osteoarthritis
Interventions
Orthovisc, Control
Device · Drug
Lead sponsor
DePuy Mitek
Industry
Eligibility
25 Years to 75 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
13
States / cities
Encinitas, California • Fresno, California • Coral Gables, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prospective Multicenter Post Approval Study of the LPS-Flex Mobile Bearing Knee

NCT00854295
View directory record Official record
Conditions
Osteoarthritis, Traumatic Arthritis, Avascular Necrosis of the Femoral Condyle, Moderate Varus, Valgus, Flexion Deformities
Interventions
NexGen LPS-Flex Mobile Bearing Knee
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
Not listed
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
3
States / cities
Tamarac, Florida • Auburn Hills, Michigan • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 31, 2026, 3:38 PM EDT
Recruiting Phase 2Phase 3 Interventional

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions
Adagrasib, Pembrolizumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
220
States / cities
Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 3:38 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Young Adult Food Messaging Experiment

NCT07768462
View directory record Official record
Conditions
Diet Quality, Young Adult Health, Communication
Interventions
Lying about unhealthy foods being healthy, Engineering foods to be addictive, Targeting groups, Piggybacking on social causes, Covering up the evidence about the harms of unhealthy foods, Control
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 29 Years
Enrollment
645 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Phase 2 Interventional Results available

Study of Arsenic Trioxide in Small Cell Lung Cancer

NCT01470248
View directory record Official record
Conditions
Lung Cancer, Cancer of Lung, Pulmonary Cancer, Pulmonary Neoplasms, Carcinoma, Small Cell
Interventions
Arsenic Trioxide
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Eat My ABCs Project

NCT05780008
View directory record Official record
Conditions
Nutrition, Healthy, Obesity, Childhood
Interventions
Eat My ABCs
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
3 Years to 5 Years
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Alpena, Michigan • Kalkaska, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Phase 4 Interventional Results available

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

NCT02891850
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 31, 2026, 3:38 PM EDT
Recruiting Not applicable Interventional

Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure

NCT07216820
View directory record Official record
Conditions
Shoulder Surgery, Obesity
Interventions
Ultrasound-Guided Interscalene Brachial Plexus Block, Phrenic-Sparing Block Combination (Experimental), Bupivacaine HCl 0.5% Injectable Solution, Dexamethasone 4mg
Procedure · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 31, 2026, 3:38 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

NCT04203160
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
CPI 613, Gemcitabine, Cisplatin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Tucson, Arizona • Chicago, Illinois • Ann Arbor, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Phase 3 Interventional Results available

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

NCT02348489
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
SGI-110 (guadecitabine), Treatment Choice
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
23
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Not applicable Interventional

Brain and Behavior Correlates of Arm Rehabilitation

NCT04989920
View directory record Official record
Conditions
Stroke, Cardiovascular
Interventions
Experimental group: CIMT group (Constraint-Induced Movement Therapy)
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Phase 2 Interventional

A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel

NCT01949324
View directory record Official record
Conditions
Macular Telangiectasia Type 2
Interventions
Ciliary neurotrophic factor (CNTF), Sham procedure, NT-501 Implant, NT-501 Implant procedure
Biological · Procedure · Device
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 31, 2026, 3:38 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Vascular Dysfunction in Hypertensive Postmenopausal Women

NCT03371823
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension
Interventions
Normotensive, Hypertensives
Other · Drug
Lead sponsor
University of Delaware
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices

NCT04865978
View directory record Official record
Conditions
Heart Failure
Interventions
Apixaban, Warfarin, LVAD implant
Drug · Device
Lead sponsor
Palak Shah
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 31, 2026, 3:38 PM EDT
Completed Not applicable Interventional

Parent Specific Depression Education and Motivation

NCT01453790
View directory record Official record
Conditions
Depressive Symptoms
Interventions
Parent-Specific Depression Education and Motivation, General Depression Education-Motivation
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 31, 2026, 3:38 PM EDT